Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United States Brent Oil Fund LP (BNO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United States Brent Oil Fund LP — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.76 (market cap $29.60B), while United States Brent Oil Fund LP trades at $50.8. The key difference: United States Brent Oil Fund LP is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BNO | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Commodities - Energy |
52-Week High | $491.22 | $60.13 |
52-Week Low | $205.48 | $27.20 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
BNO, tracking Brent crude oil futures, trades at $50.73, up 1.24% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights supply disruptions from the Strait of Hormuz standoff and OPEC's lowered demand forecasts, creating volatility. The stock lacks traditional financial ratios as it is an ETF, with performance tied directly to oil price movements and geopolitical developments.
Outlook hinges on oil market dynamics, with upside from sustained supply risks but downside from demand weakness. Risks include Middle East tensions and inventory builds. Analysts monitor EIA data and OPEC actions for direction, with current sentiment mixed amid headline-driven price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →
